Clinical trial NCT03508739: Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition
Official title: Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type 2
Pre-diabetic
Hypertension
Elevated Blood Pressure
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2018-04-26
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: prospective randomized, double-blind, crossover study, mechanistic/ translational study (not to change labeling or marketing, not classic phase 3 or 4 study), IND exempt
Primary purpose: OTHER

Brief summary: Type 2 diabetes is common, increases in prevalence with age, and patients with diabetes have an increased risk of cardiovascular disease. A relatively new cardiovascular medication currently used for the treatment of heart failure in the United States inhibits an enzyme that breaks down a variety of signaling hormones. This clinical trial tests if it may also be a target for the treatment of diabetes by decreasing the breakdown of a hormone that increases insulin release after a meal.

Detailed description: This study will test the hypothesis that neprilysin inhibition with sacubitril/valsartan will increase endogenous glucagon-like peptide-1 (GLP-1) after a mixed meal compared to valsartan. The primary statistical analysis will be within subject comparison (paired t-test or nonparametric equivalent) of area under the curve intact GLP-1 after the meal during sacubitril/valsartan compared to valsartan. Neprilysin inhibition may be a new drug target for the treatment of type 2 diabetes by increasing intact GLP-1 and may be of particular benefit to individuals with increased risk of hypoglycemia and cardiovascular disease.

Eligibility criteria: Inclusion Criteria:

1. Men and women ages 18-80 years
2. Type 2 diabetes mellitus (T2DM) or pre-diabetes, controlled by diet alone or metformin therapy and elevated blood pressure

   1. Pre-diabetes is defined as fasting plasma glucose of 100-125 mg/dL, plasma glucose of 140-199 mg/dL two hours after 75g oral glucose load, or hemoglobin A1C 5.7-6.4%. T2DM is defined as fasting plasma glucose of ≥126 mg/dL, plasma glucose of ≥200 mg/dL two hours after 75g oral glucose load, or hemoglobin A1C ≥6.5%.
   2. Elevated blood pressure is defined as systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥80 mmHg on three occasions or therapy with antihypertensive medication(s) for a minimum of three months.
3. For female subjects, the following conditions must be met:

   1. Postmenopausal status for at least one year or
   2. Status post-surgical sterilization, or
   3. If childbearing potential, utilization of birth control (barrier methods, abstinence, hormonal contraception, etc) and willingness to undergo regular beta hCG monitoring prior to drug treatment and on each study day. (Valsartan is pregnancy category D.)

Exclusion Criteria:

1. Type 1 diabetes
2. Poorly controlled T2DM, defined as hemoglobin A1C ≥8.7%
3. Use of anti-diabetic medications other than metformin for over 24 months prior to initiation of the study.
4. Requiring the need for insulin therapy
5. Secondary hypertension
6. Severe hypertension requiring the use of more than two anti-hypertensive agents other than a stable dose of diuretic or blood pressure \> 180/110 mmHg
7. Subjects who have participated in a weight-reduction program during the last 6 months and whose weight has increased or decreased more than 5 kg over the preceding 6 months
8. Pregnancy or breastfeeding
9. History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, angiotensin converting enzyme inhibitors, ARBs, or NEP inhibitors, as well as known or suspected contraindications to the study drugs
10. History of angioedema
11. History of pancreatitis or known pancreatic lesions
12. Clinically significant gastrointestinal impairment that could interfere with drug absorption
13. Significant cardiovascular disease such as myocardial infarction or cardiovascular surgery or angioplasty within six months prior to enrollment, presence of angina pectoris, arrhythmia with history of or risk of syncopal episodes or need for antiarrhythmic therapy, congestive heart failure (LV hypertrophy and diastolic dysfunction acceptable), deep vein thrombosis, pulmonary embolism, second- or third-degree AV block, mitral valve stenosis, hypertrophic cardiomyopathy, or coronary or carotid artery disease likely to require surgical or percutaneous intervention within six months of screening
14. Impaired hepatic function (aspartate amino transaminase \[AST\] and/or alanine amino transaminase \[ALT\] \>3 x upper limit of normal range)
15. Impaired renal function (eGFR\< 50mL/min/1.73m2 as determined by the MDRD equation)
16. History or presence of immunological or hematological disorders
17. Serum potassium \>5.2 mmol/L at screening
18. History of serious neurologic disease such as cerebral hemorrhage, stroke, seizure, or transient ischemic attack within six months
19. Hematocrit \<35%
20. Diagnosis of asthma requiring use of inhaled beta agonist more than once a week
21. Clinically significant gastrointestinal impairment that could interfere with drug absorption
22. Any underlying or acute disease requiring regular medication which could possibly pose a threat to the subject or make implementation of the protocol or interpretation of the study results difficult, such as arthritis treated with daily use of non-steroidal anti-inflammatory drugs
23. Treatment with chronic systemic glucocorticoid therapy within the last year
24. Treatment with systemic glucocorticoid therapy acutely within six weeks prior to enrollment
25. Treatment with lithium salts
26. History of alcohol or drug abuse
27. Treatment with anticoagulation
28. Treatment with any investigational drug in the one month preceding the study
29. Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study
30. Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

Primary outcomes:
measure: Intact glucagon like peptide-1 (GLP-1) levels after the mixed meal
timeFrame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
Secondary outcomes:
measure: Insulin levels after the mixed meal
timeFrame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
measure: Blood glucose levels after the mixed meal
timeFrame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
measure: Triglyceride levels after the mixed meal
timeFrame: This will be measured just before the meal and after the meal at pre-specified time points for a total of four hours. (Time points 0 to 4 hours)
measure: Neprilysin enzyme (drug) activity at baseline, during sacubitril/valsartan, and during valsartan
timeFrame: Time points -120 min (before drug given) and 0 min (2 hours after drug dose, just prior to the meal)
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Jessica R Wilson, MD, MSCI
role: PRINCIPAL_INVESTIGATOR
References: